[1]Bachurin S, Bukatina E, Lermontova N, et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer[J]. Ann N Y Acad Sci, 2001,939:425-435. [2] Bezprozvanny I, Hayden MR. Deranged neuronal calcium signaling and Huntington disease[J]. Biochem Biophys Res Commun ,2004, 322(4):1310-1317. [3] Tang TS, Slow E, Lupu V, et al. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease [J].Proc Natl Acad Sci USA, 2005, 102(7):2602-2607. [4] Wu J, Li Q, Bezprozvanny I, et al. Evaluation of Dimebon in cellular model of Huntington's disease[J].Mol Neurodegener, 2008,3:15. [5] Grigorev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanisms of dimebon and memantine on AMPAand NMDA-subtypes glutamate receptors in rat cerebral neurons[J]. Bull Exp Biol Med ,2003, 136(5):474-477. [6] Lermontova NN, Redkozubov AE, Shevtsova EF,et al. Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels[J].Bull Exp Biol Med ,2001, 132(5):1079-1083. [7] Bachurin SO, Shevtsova EP, Kireeva EG, et al. Mitochondria as a target for neurotoxins and neuroprotective agents[J]. Ann N Y Acad Sci,2003, 993:334-344. [8] Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition,activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease:a randomised, double-blind,placebo-controlled study [J]. Lancet,2008,372(9634):207-215. |